AlphAIalphai — Financial news for AI agents
rttnews.comJUL 304 min read$MDXG

MiMedx To Acquire Sanara MedTech In $350 Million Deal; Stock Up

MiMed Group Inc. (MDXG) agreed to acquire Sanara MedTech Inc. (SMTI) for $35 per share, about $350 million. Sanara’s products include CellerateRX and BIASURGE, and it plans a 2027 launch of OsStic BioAdhesive, FDA Breakthrough-designated. MiMedx projects combined 2027 revenue over $400 million and adjusted EBITDA margins above 20%, with $20M+ synergies. SMTI is up 12.1% to $33.91.

Original reporting
rttnews.com
Published Jul 30, 2026, 4:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 30, 2026, 5:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
MiMedx To Acquire Sanara MedTech In $350 Million Deal; Stock Up — source image
Source · rttnews.com
Decision brief

The 30-second read

$MDXGBullishHigh
01

Why it matters

The acquisition combines Sanara’s surgical technologies with MiMedx’s portfolio, aiming to expand operating room presence and deliver revenue growth plus cost synergies.

02

Market read

A disclosed $35/share, ~$350 million acquisition with management-stated 2027 targets is a direct catalyst for MDXG and deal-spread positioning.

03

What to watch

Closing conditions, financing structure, and any FDA/commercial adoption timelines for OsStic BioAdhesive are not detailed here, which can materially affect valuation.

Relevance 9/10Novelty 9/10Timing: deal announcement reported today, with stock already up 12%

Background

MiMedx (MDXG) is a regenerative medicines biopharma company; Sanara (SMTI) focuses on regenerative surgical products and is preparing a 2027 commercial launch of OsStic BioAdhesive.

Company-level read

Ticker impact

$MDXGBullishMedium confidence
Context

MiMedx agreed to acquire Sanara MedTech for about $350 million, projecting 2027 revenue above $400 million and EBITDA margins above 20%.

Expected impact

Likely supportive for MDXG while deal completion risk remains, with volatility around regulatory/closing milestones.

Evidence & confidence

The article discloses a specific $35/share offer, deal value, and management-stated 2027 financial targets, which are actionable for deal-spread and positioning.

Market effects

Sector

Signals continued consolidation in regenerative surgical products, potentially improving sentiment for adjacent surgical device and regenerative medicine names.

Regional

Primarily US-focused biotech M&A sentiment.

Global

Limited direct global read-through beyond US regenerative surgery consolidation.

Counterpoint

What could challenge this read

Projected 2027 revenue and EBITDA margins may be optimistic versus execution and integration risk, so the deal spread could widen if diligence or regulatory hurdles emerge.

Key entities

  • acquirer
    MiMed Group Inc.

    Agreed to acquire Sanara MedTech in a transaction valued at about $350 million.

  • target
    Sanara MedTech Inc.

    Flagship regenerative surgical products and preparing a 2027 commercial launch of OsStic BioAdhesive.

  • product
    OsStic BioAdhesive Advanced Bone Fixation

    A device designated as Breakthrough by the U.S. FDA, targeted for 2027 commercial launch.

Read at source← All news

Also covered by

1 outlet

Related articles

JUL 31
$MDXGMedAI 9/10

MiMedx to acquire Sanara MedTech in $350M deal

MiMedx Group agreed to acquire Sanara MedTech in a cash-and-stock deal valued at about $350 million enterprise value, per MiMedx’s July 30 release. Sanara shareholders will receive $33 cash plus 0.4735 MiMedx shares per share, totaling $35 per share. The stock value uses MiMedx’s $4.22 average price. Deal expected to close by year-end, subject to approvals; combined 2027 revenue projected above $400 million.

beckersspine.com4 min
JUL 30
$MDXGHighAI 10/10

MIMEDX to Acquire Sanara MedTech – Ortho Spine News

Transformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgical Subspecialties Accelerates MIMEDX’s Strategic Priority to Expand Surgical Footprint, Nearly Doubling Surgical Revenue Immediately Accretive to Revenue Growth, Gross Margin and Adjusted EBITDA Margin Anticipates Over $20 Million in Run-Rate Cost Synergies Conference Call to Discuss Transaction Alongside MIMEDX’s Second Quarter 2026 Operating and Financial Results Today at 4:30pm...

orthospinenews.com4 min
JUL 30
MedAI 8/10

Joele Frank Works Sanara MedTech's Deal

Sanara MedTech, a Fort Worth surgical tissue repair products maker, is being acquired by MiMedx Group for cash and stock valued at $350M, according to the deal announcement. MiMedx expects the combined business to have over $400M in annual revenue and to accelerate double-digit growth. The transaction is expected to close by year-end.

odwyerpr.com2 min
JUL 30
$MDXGMed

MiMedx: Q2 Earnings Snapshot

MiMedx Group Inc. (MDXG) reported a Q2 loss of $14.8 million, or 10 cents per share. Adjusted for non-recurring items, it posted a 5 cents per share loss. Revenue was $64.4 million. The company expects full-year revenue of $260 million to $290 million.

local3news.com2 min
JUL 30
$SPRCHighAI 8/10

Top Biotech Gainers: SPRC On Watch, AVTR, NEO Boost Full-Year Outlook, SMTI Scooped Up

Biotech gainers included SciSparc (SPRC) after its subsidiary NeuroThera Labs completed internal validation of a quantum sampling platform. Avantor (AVTR) rose after Q2 results and raised 2026 adjusted EPS to $0.80-$0.83. NeoGenomics (NEO) lifted 2026 revenue guidance to $802-$806M. Other movers: Alvotech (ALVO) on FDA facility inspection, Sanara MedTech (SMTI) to be acquired by MiMedx (MDXG), and LB Pharmaceuticals (LBRX) after a ~$150M private placement.

rttnews.com3 min